{"id":"chlorothiazide","rwe":[],"_fda":{"id":"dda0054a-e39b-4667-addf-e999a34806d8","set_id":"187240e9-1eed-45ec-befb-18647d175112","openfda":{"unii":["SN86FG7N2K"],"route":["INTRAVENOUS"],"rxcui":["484152"],"spl_id":["dda0054a-e39b-4667-addf-e999a34806d8"],"brand_name":["CHLOROTHIAZIDE SODIUM"],"spl_set_id":["187240e9-1eed-45ec-befb-18647d175112"],"package_ndc":["47335-330-40"],"product_ndc":["47335-330"],"generic_name":["CHLOROTHIAZIDE SODIUM"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CHLOROTHIAZIDE SODIUM"],"manufacturer_name":["Sun Pharmaceutical Industries, Inc."],"application_number":["ANDA091546"],"is_original_packager":[true]},"version":"5","warnings":["WARNINGS Intravenous use in infants and children has been limited and is not generally recommended. Use with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Thiazides may add to or potentiate the action of other antihypertensive drugs. Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma. The possibility of exacerbation or activation of systemic lupus erythematosus has been reported. Lithium generally should not be given with diuretics (see PRECAUTIONS, Drug Interactions )."],"pregnancy":["Pregnancy Teratogenic Effects Pregnancy Category C: Although reproduction studies performed with chlorothiazide doses of 50 mg/kg/day in rabbits, 60 mg/kg/day in rats and 500 mg/kg/day in mice revealed no external abnormalities of the fetus or impairment of growth and survival of the fetus due to chlorothiazide, such studies did not include complete examinations for visceral and skeletal abnormalities. It is not known whether chlorothiazide can cause fetal harm when administered to a pregnant woman; however, thiazides cross the placental barrier and appear in cord blood. Chlorothiazide should be used during pregnancy only if clearly needed (see INDICATIONS AND USAGE ). Nonteratogenic Effects: Chlorothiazide may cause fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions which have occurred in the adult."],"overdosage":["OVERDOSAGE The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. In the event of overdosage, symptomatic and supportive measures should be employed. Correct dehydration, electrolyte imbalance, hepatic coma and hypotension by established procedures. If required, give oxygen or artificial respiration for respiratory impairment. The degree to which chlorothiazide sodium is removed by hemodialysis has not been established. The intravenous LD 50 of chlorothiazide in the mouse is 1.1 g/kg."],"description":["DESCRIPTION Chlorothiazide sodium is a diuretic and antihypertensive. It is 6-chloro- 2 H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide monosodium salt and its molecular weight is 317.71. Its molecular formula is C 7 H 5 ClN 3 NaO 4 S 2 and its structural formula is: Chlorothiazide sodium for injection, USP is a sterile lyophilized white powder and is supplied in a vial containing: Chlorothiazide sodium equivalent to chlorothiazide USP........................................ 500 mg Inactive ingredients: Mannitol .................................................................................................................. 250 mg Sodium hydroxide to adjust pH. Chlorothiazide is a diuretic and antihypertensive. It is 6-chloro- 2 H -1,2,4- benzothiadiazine-7-sulfonamide 1,1-dioxide. Its molecular formula is C 7 H 6 ClN 3 O 4 S 2 and its structural formula is: It is a white, or practically white, crystalline powder with a molecular weight of 295.72, which is insoluble in water, but readily soluble in dilute aqueous sodium hydroxide. It is soluble in urine to the extent of about 150 mg per 100 mL at pH 7. chlorothiazide-Sodium-structure chlorothiazide-structure"],"precautions":["PRECAUTIONS General All patients receiving diuretic therapy should be observed for evidence of fluid or electrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Warning signs or symptoms of fluid and electrolyte imbalance, irrespective of cause, include dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, confusion, seizures, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting. Hypokalemia may develop especially with brisk diuresis, when severe cirrhosis is present or after prolonged therapy. Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Hypokalemia may cause cardiac arrhythmias and may also sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular irritability). Hypokalemia may be avoided or treated by use of potassium-sparing diuretics or potassium supplements such as foods with a high potassium content. Although any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or renal disease), chloride replacement may be required in the treatment of metabolic alkalosis. Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt, except in rare instances when the hyponatremia is life-threatening. In actual salt depletion, appropriate replacement is the therapy of choice. Hyperuricemia may occur or acute gout may be precipitated in certain patients receiving thiazides. In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required. Hyperglycemia may occur with thiazide diuretics. Thus latent diabetes mellitus may become manifest during thiazide therapy. The antihypertensive effects of the drug may be enhanced in the postsympathectomy patient. If progressive renal impairment becomes evident, consider withholding or discontinuing diuretic therapy. Thiazides have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia. Thiazides may decrease urinary calcium excretion. Thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function. Increases in cholesterol and triglyceride levels may be associated with thiazide diuretic therapy. Laboratory Tests Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be done at appropriate intervals. Drug Interactions When given concurrently the following drugs may interact with thiazide diuretics. Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. Antidiabetic drugs - (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. Other antihypertensive drugs - additive effect or potentiation. Corticosteroids, ACTH - intensified electrolyte depletion, particularly hypokalemia. Pressor amines (e.g., norepinephrine) - possible decreased response to pressor amines but not sufficient to preclude their use. Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) - possible increased responsiveness to the muscle relaxant. Lithium - generally should not be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity. Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide sodium. Non-steroidal Anti-inflammatory Drugs - In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when chlorothiazide sodium and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained. Drug/Laboratory Test Interactions Thiazides should be discontinued before carrying out tests for parathyroid function (see PRECAUTIONS, General ). Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with chlorothiazide. Chlorothiazide was not mutagenic in vitro in the Ames microbial mutagen test (using a maximum concentration of 5 mg/plate and Salmonella typhimurium strains TA98 and TA100) and was not mutagenic and did not induce mitotic nondisjunction in diploid-strains of Aspergillus nidulans . Chlorothiazide had no adverse effects on fertility in female rats at doses up to 60 mg/kg/day and no adverse effects on fertility in male rats at doses up to 40 mg/kg/day. These doses are 1.5 and 1 times 1 the recommended maximum human dose, respectively, when compared on a body weight basis. 1 Calculations based on a human body weight of 50 kg. Pregnancy Teratogenic Effects Pregnancy Category C: Although reproduction studies performed with chlorothiazide doses of 50 mg/kg/day in rabbits, 60 mg/kg/day in rats and 500 mg/kg/day in mice revealed no external abnormalities of the fetus or impairment of growth and survival of the fetus due to chlorothiazide, such studies did not include complete examinations for visceral and skeletal abnormalities. It is not known whether chlorothiazide can cause fetal harm when administered to a pregnant woman; however, thiazides cross the placental barrier and appear in cord blood. Chlorothiazide should be used during pregnancy only if clearly needed (see INDICATIONS AND USAGE ). Nonteratogenic Effects: Chlorothiazide may cause fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions which have occurred in the adult. Nursing Mothers Because of the potential for serious adverse reactions in nursing infants from chlorothiazide sodium, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use Safety and effectiveness of chlorothiazide sodium in pediatric patients have not been established. Geriatric Use Clinical studies of chlorothiazide sodium did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see WARNINGS )."],"how_supplied":["HOW SUPPLIED Chlorothiazide sodium for injection, USP is a dry, sterile lyophilized white to off white powder usually in cake form, supplied in vials containing chlorothiazide sodium equivalent to 500 mg of chlorothiazide USP. NDC 47335-330-40 Storage Store lyophilized powder at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature]. For single dose only. Use solution immediately after reconstitution. (See DOSAGE AND ADMINISTRATION, Directions for Reconstitution .) Discard unused portion of the reconstituted solution."],"geriatric_use":["Geriatric Use Clinical studies of chlorothiazide sodium did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see WARNINGS )."],"pediatric_use":["Pediatric Use Safety and effectiveness of chlorothiazide sodium in pediatric patients have not been established."],"effective_time":"20250321","nursing_mothers":["Nursing Mothers Because of the potential for serious adverse reactions in nursing infants from chlorothiazide sodium, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother."],"laboratory_tests":["Laboratory Tests Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be done at appropriate intervals."],"adverse_reactions":["ADVERSE REACTIONS The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity. Body as a Whole: Weakness. Cardiovascular: Hypotension including orthostatic hypotension (may be aggravated by alcohol, barbiturates, narcotics or antihypertensive drugs). Digestive: Pancreatitis, jaundice (intrahepatic cholestatic jaundice), diarrhea, vomiting, sialadenitis, cramping, constipation, gastric irritation, nausea, anorexia. Hematologic: Aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia. Hypersensitivity: Anaphylactic reactions, necrotizing angiitis (vasculitis and cutaneous vasculitis), respiratory distress including pneumonitis and pulmonary edema, photosensitivity, fever, urticaria, rash, purpura. Metabolic: Electrolyte imbalance (see PRECAUTIONS ), hyperglycemia, glycosuria, hyperuricemia. Musculoskeletal: Muscle spasm. Nervous System/Psychiatric: Vertigo, paresthesias, dizziness, headache, restlessness. Skin: Erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, alopecia. Special Senses: Transient blurred vision, xanthopsia. Renal: Renal failure, renal dysfunction, interstitial nephritis, (see WARNINGS ); hematuria (following intravenous use). Urogenital: Impotence. Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn."],"contraindications":["CONTRAINDICATIONS Anuria. Hypersensitivity to any component of this product or to other sulfonamide-derived drugs."],"drug_interactions":["Drug Interactions When given concurrently the following drugs may interact with thiazide diuretics. Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. Antidiabetic drugs - (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. Other antihypertensive drugs - additive effect or potentiation. Corticosteroids, ACTH - intensified electrolyte depletion, particularly hypokalemia. Pressor amines (e.g., norepinephrine) - possible decreased response to pressor amines but not sufficient to preclude their use. Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) - possible increased responsiveness to the muscle relaxant. Lithium - generally should not be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity. Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide sodium. Non-steroidal Anti-inflammatory Drugs - In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when chlorothiazide sodium and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained."],"general_precautions":["General All patients receiving diuretic therapy should be observed for evidence of fluid or electrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Warning signs or symptoms of fluid and electrolyte imbalance, irrespective of cause, include dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, confusion, seizures, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting. Hypokalemia may develop especially with brisk diuresis, when severe cirrhosis is present or after prolonged therapy. Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Hypokalemia may cause cardiac arrhythmias and may also sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular irritability). Hypokalemia may be avoided or treated by use of potassium-sparing diuretics or potassium supplements such as foods with a high potassium content. Although any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or renal disease), chloride replacement may be required in the treatment of metabolic alkalosis. Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt, except in rare instances when the hyponatremia is life-threatening. In actual salt depletion, appropriate replacement is the therapy of choice. Hyperuricemia may occur or acute gout may be precipitated in certain patients receiving thiazides. In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required. Hyperglycemia may occur with thiazide diuretics. Thus latent diabetes mellitus may become manifest during thiazide therapy. The antihypertensive effects of the drug may be enhanced in the postsympathectomy patient. If progressive renal impairment becomes evident, consider withholding or discontinuing diuretic therapy. Thiazides have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia. Thiazides may decrease urinary calcium excretion. Thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function. Increases in cholesterol and triglyceride levels may be associated with thiazide diuretic therapy."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY The mechanism of the antihypertensive effect of thiazides is unknown. Chlorothiazide does not usually affect normal blood pressure. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are approximately equal in their diuretic efficacy. Chlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. After oral use diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours. Following intravenous use of chlorothiazide sodium, onset of the diuretic action occurs in 15 minutes and the maximal action in 30 minutes. Pharmacokinetics and Metabolism Chlorothiazide is not metabolized but is eliminated rapidly by the kidney; 96 percent of an intravenous dose is excreted unchanged in the urine within 23 hours. The plasma half-life of chlorothiazide is 45 to 120 minutes. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk."],"indications_and_usage":["INDICATIONS AND USAGE Chlorothiazide sodium for injection is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorothiazide sodium for injection has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Use in Pregnancy Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see PRECAUTIONS, Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate."],"spl_unclassified_section":["Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 Manufactured by: Sun Pharmaceutical Industries Ltd. Halol-Baroda Highway, Halol-389 350, Gujarat, India. or Manufactured by: Sun Pharmaceutical Industries Ltd., India At M/s. Immacule Lifesciences Pvt. Ltd. Vill-Thanthewal, Ropar Road, Nalagarh-174101, Dist-Solan (H.P.), India ISS. 09/2024 5252845"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Chlorothiazide sodium for injection should be reserved for patients unable to take oral medication or for emergency situations. Therapy should be individualized according to patient response. Use the smallest dosage necessary to achieve the required response. Intravenous use in infants and children has been limited and is not generally recommended. When medication can be taken orally, therapy with chlorothiazide tablets or oral suspension may be substituted for intravenous therapy, using the same dosage schedule as for the parenteral route. Chlorothiazide sodium for injection may be given slowly by direct intravenous injection or by intravenous infusion. Extravasation must be rigidly avoided. Do not give subcutaneously or intramuscularly. The usual adult dosage is 500 mg to 1 g once or twice a day. Many patients with edema respond to intermittent therapy, i.e., administration on alternate days or on three to five days each week. With an intermittent schedule, excessive response and the resulting undesirable electrolyte imbalance are less likely to occur. Directions for Reconstitution Use aseptic technique. Because chlorothiazide sodium for injection contains no preservative, a fresh solution should be prepared immediately prior to each administration, and the unused portion should be discarded. Add 18 mL of Sterile Water for Injection to the vial to form an isotonic solution for intravenous injection. Never add less than 18 mL. When reconstituted with 18 mL of Sterile Water, the final concentration of intravenous chlorothiazide sodium is 28 mg/mL. The reconstituted solution is clear and essentially free from visible particles. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to use whenever solution and container permit. The solution is compatible with dextrose or sodium chloride solutions for intravenous infusion. Avoid simultaneous administration of solutions of chlorothiazide with whole blood or its derivatives."],"spl_product_data_elements":["CHLOROTHIAZIDE SODIUM CHLOROTHIAZIDE SODIUM CHLOROTHIAZIDE SODIUM CHLOROTHIAZIDE MANNITOL SODIUM HYDROXIDE"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - CARTON NDC 47335-330-40 Chlorothiazide Sodium for Injection, USP 500 mg/vial STERILE LYOPHILIZED FOR THE PREPARATION OF INTRAVENOUS SOLUTIONS Rx only One Single Dose Vial SUN PHARMA chlorothiazide-carton"],"drug_and_or_laboratory_test_interactions":["Drug/Laboratory Test Interactions Thiazides should be discontinued before carrying out tests for parathyroid function (see PRECAUTIONS, General )."],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with chlorothiazide. Chlorothiazide was not mutagenic in vitro in the Ames microbial mutagen test (using a maximum concentration of 5 mg/plate and Salmonella typhimurium strains TA98 and TA100) and was not mutagenic and did not induce mitotic nondisjunction in diploid-strains of Aspergillus nidulans . Chlorothiazide had no adverse effects on fertility in female rats at doses up to 60 mg/kg/day and no adverse effects on fertility in male rats at doses up to 40 mg/kg/day. These doses are 1.5 and 1 times 1 the recommended maximum human dose, respectively, when compared on a body weight basis. 1 Calculations based on a human body weight of 50 kg."]},"tags":[{"label":"Thiazide Diuretic","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Solute carrier family 12 member 3","category":"target"},{"label":"SLC12A3","category":"gene"},{"label":"CA2","category":"gene"},{"label":"C03AA04","category":"atc"},{"label":"Oral","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Suspension","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Chronic heart failure","category":"indication"},{"label":"Edema","category":"indication"},{"label":"Edema due to Hepatic Cirrhosis","category":"indication"},{"label":"Edema due to Nephrotic Syndrome","category":"indication"},{"label":"Hypertension with Left Ventricular Hypertrophy","category":"indication"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Salix Pharms","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Diuretics","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Natriuretic Agents","category":"pharmacology"},{"label":"Sodium Chloride Symporter Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"83 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"81 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"77 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"72 reports"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"71 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"65 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"64 reports"},{"date":"","signal":"RESPIRATORY FAILURE","source":"FDA FAERS","actionTaken":"63 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"59 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"56 reports"}],"drugInteractions":[{"url":"/drug/cisapride","drug":"cisapride","action":"Monitor closely","effect":"May interact with Cisapride","source":"DrugCentral","drugSlug":"cisapride"},{"url":"/drug/dofetilide","drug":"dofetilide","action":"Avoid combination","effect":"May interact with Dofetilide","source":"DrugCentral","drugSlug":"dofetilide"},{"url":"/drug/lithium","drug":"lithium","action":"Avoid combination","effect":"May interact with Lithium","source":"DrugCentral","drugSlug":"lithium"}],"commonSideEffects":[{"effect":"Pancreatitis","drugRate":"reported","severity":"unknown"},{"effect":"Hypotension","drugRate":"reported","severity":"unknown"},{"effect":"Leukopenia","drugRate":"reported","severity":"unknown"},{"effect":"Thrombocytopenia","drugRate":"reported","severity":"unknown"},{"effect":"Aplastic anemia","drugRate":"reported","severity":"unknown"},{"effect":"Agranulocytosis","drugRate":"reported","severity":"unknown"},{"effect":"Hemolytic anemia","drugRate":"reported","severity":"unknown"},{"effect":"Necrotizing angiitis","drugRate":"reported","severity":"unknown"},{"effect":"Pneumonitis","drugRate":"reported","severity":"unknown"},{"effect":"Pulmonary edema","drugRate":"reported","severity":"unknown"},{"effect":"Electrolyte imbalance","drugRate":"reported","severity":"unknown"},{"effect":"Hyperglycemia","drugRate":"reported","severity":"unknown"},{"effect":"Glycosuria","drugRate":"reported","severity":"unknown"},{"effect":"Hyperuricemia","drugRate":"reported","severity":"unknown"},{"effect":"Muscle spasm","drugRate":"reported","severity":"unknown"},{"effect":"Vertigo","drugRate":"reported","severity":"unknown"},{"effect":"Paresthesias","drugRate":"reported","severity":"unknown"},{"effect":"Dizziness","drugRate":"reported","severity":"unknown"},{"effect":"Headache","drugRate":"reported","severity":"unknown"},{"effect":"Restlessness","drugRate":"reported","severity":"unknown"},{"effect":"Erythema multiforme","drugRate":"reported","severity":"unknown"},{"effect":"Stevens-Johnson syndrome","drugRate":"reported","severity":"unknown"},{"effect":"Exfoliative dermatitis","drugRate":"reported","severity":"unknown"},{"effect":"Toxic epidermal necrolysis","drugRate":"reported","severity":"unknown"},{"effect":"Alopecia","drugRate":"reported","severity":"unknown"},{"effect":"Impotence","drugRate":"reported","severity":"unknown"},{"effect":"Renal failure","drugRate":"reported","severity":"unknown"},{"effect":"Renal dysfunction","drugRate":"reported","severity":"unknown"},{"effect":"Interstitial nephritis","drugRate":"reported","severity":"unknown"},{"effect":"Hematuria","drugRate":"reported","severity":"unknown"}],"contraindications":["Acidosis","Acute cerebrovascular insufficiency","Acute exacerbation of asthma","Acute hepatic failure","Acute hepatitis","Acute nephropathy","Acute pancreatitis","Acute vomiting","Anaphylaxis","Anemia","Angina pectoris","Angioedema","Anuria","Aortic valve stenosis","Asthma","Autoimmune hemolytic anemia","Azotemia","Benign intracranial hypertension","Bone marrow depression","Bronchospasm","Calculus in biliary tract","Cardiogenic shock","Cerebrovascular accident","Chronic bronchitis","Chronic disease of respiratory system"],"specialPopulations":{"Pregnancy":"Pregnancy Category C: Although reproduction studies performed with chlorothiazide doses of 50 mg/kg/day in rabbits, 60 mg/kg/day in rats and 500 mg/kg/day in mice revealed no external abnormalities of the fetus or impairment of growth and survival of the fetus due to chlorothiazide, such studies did not include complete examinations for visceral and skeletal abnormalities. It is not known whether chlorothiazide can cause fetal harm when administered to pregnant woma","Geriatric use":"Clinical studies of DIURIL did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, ","Paediatric use":"There are no well-controlled clinical trials in pediatric patients. Information on dosing in this age group is supported by evidence from empiric use in pediatric patients and published literature regarding the treatment of hypertension in such patients (see DOSAGE AND ADMINISTRATION, Infants and Children)."}},"trials":[],"aliases":[],"company":"Salix Pharms","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CHLOROTHIAZIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:10:24.232482+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:10:31.543650+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:10:22.792860+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHLOROTHIAZIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:10:32.341075+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:10:21.302195+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:11:19.197453+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:10:21.302409+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:10:33.816114+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Thiazide-sensitive sodium-chloride cotransporter inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:10:32.893666+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL842/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:10:32.810351+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA091546","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:10:21.302427+00:00"}},"allNames":"diuril","offLabel":[],"synonyms":["chlorothiazide","chlorothiazide sodium"],"timeline":[{"date":"1958-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from OAK PHARMS AKORN to Salix Pharms"},{"date":"1958-09-04","type":"positive","source":"DrugCentral","milestone":"FDA approval (Oak Pharms Akorn)"}],"approvals":[{"date":"1958-09-04","orphan":false,"company":"OAK PHARMS AKORN","regulator":"FDA"}],"brandName":"Diuril","ecosystem":[{"indication":"Chronic heart failure","otherDrugs":[{"name":"candesartan cilexetil","slug":"candesartan-cilexetil","company":"Astrazeneca"},{"name":"captopril","slug":"captopril","company":"Par Pharm"},{"name":"carvedilol","slug":"carvedilol","company":"Smithkline Beecham"},{"name":"dapagliflozin","slug":"dapagliflozin","company":"Astrazeneca Ab"}],"globalPrevalence":64000000},{"indication":"Edema","otherDrugs":[{"name":"acetazolamide","slug":"acetazolamide","company":"Teva Branded Pharm"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"bumetanide","slug":"bumetanide","company":""},{"name":"chlortalidone","slug":"chlortalidone","company":""}],"globalPrevalence":null},{"indication":"Edema due to Hepatic Cirrhosis","otherDrugs":[{"name":"bumetanide","slug":"bumetanide","company":""},{"name":"furosemide","slug":"furosemide","company":"Sanofi Aventis Us"},{"name":"hydrochlorothiazide","slug":"hydrochlorothiazide","company":""},{"name":"spironolactone","slug":"spironolactone","company":"Gd Searle Llc"}],"globalPrevalence":null},{"indication":"Edema due to Nephrotic Syndrome","otherDrugs":[{"name":"hydrochlorothiazide","slug":"hydrochlorothiazide","company":""},{"name":"spironolactone","slug":"spironolactone","company":"Gd Searle Llc"}],"globalPrevalence":8800},{"indication":"Hypertension with Left Ventricular Hypertrophy","otherDrugs":[{"name":"hydrochlorothiazide","slug":"hydrochlorothiazide","company":""},{"name":"losartan","slug":"losartan","company":"Merck Sharp Dohme"}],"globalPrevalence":1280000000},{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null},{"indication":"Hypertensive urgency","otherDrugs":[{"name":"diazoxide","slug":"diazoxide","company":""},{"name":"fenoldopam","slug":"fenoldopam","company":"Hospira"},{"name":"hydrochlorothiazide","slug":"hydrochlorothiazide","company":""},{"name":"losartan","slug":"losartan","company":"Merck Sharp Dohme"}],"globalPrevalence":null},{"indication":"Peripheral Edema due to Chronic Heart Failure","otherDrugs":[{"name":"acetazolamide","slug":"acetazolamide","company":"Teva Branded Pharm"},{"name":"bumetanide","slug":"bumetanide","company":""},{"name":"chlortalidone","slug":"chlortalidone","company":""},{"name":"ethacrynic acid","slug":"ethacrynic-acid","company":"Aton"}],"globalPrevalence":64000000}],"mechanism":{"target":"Solute carrier family 12 member 3","novelty":"Follow-on","targets":[{"gene":"SLC12A3","source":"DrugCentral","target":"Solute carrier family 12 member 3","protein":"Solute carrier family 12 member 3"},{"gene":"CA2","source":"DrugCentral","target":"Carbonic anhydrase 2","protein":"Carbonic anhydrase 2"}],"modality":"Small Molecule","drugClass":"Thiazide Diuretic","explanation":"","oneSentence":"","technicalDetail":"Diuril acts as a competitive inhibitor of the sodium-chloride cotransporter (NCC) in the distal convoluted tubule of the kidneys, reducing sodium reabsorption and increasing sodium and water excretion."},"commercial":{"launchDate":"1958","_launchSource":"DrugCentral (FDA 1958-09-04, OAK PHARMS AKORN)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/609","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CHLOROTHIAZIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHLOROTHIAZIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T09:35:08.680473","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:11:19.465137+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"bendroflumethiazide","drugSlug":"bendroflumethiazide","fdaApproval":"1959-12-07","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"hydroflumethiazide","drugSlug":"hydroflumethiazide","fdaApproval":"1959-07-22","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"hydrochlorothiazide","drugSlug":"hydrochlorothiazide","fdaApproval":"1959-02-12","patentExpiry":"Jan 23, 2044","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"polythiazide","drugSlug":"polythiazide","fdaApproval":"1961-09-26","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"trichlormethiazide","drugSlug":"trichlormethiazide","fdaApproval":"1960-03-09","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"methylclothiazide","drugSlug":"methylclothiazide","fdaApproval":"1960-10-21","relationship":"same-class"},{"drugName":"cyclothiazide","drugSlug":"cyclothiazide","fdaApproval":"1982-06-08","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"chlorothiazide","indications":{"approved":[{"id":"chlorothiazide-edema-in-congestive-heart-fail","name":"Edema in Congestive Heart Failure","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with edema due to congestive heart failure","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with edema due to congestive heart failure","diagnosticRequired":null,"brandNameForIndication":"Diuril"},{"id":"chlorothiazide-edema-in-hepatic-cirrhosis","name":"Edema in Hepatic Cirrhosis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with edema due to hepatic cirrhosis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with edema due to hepatic cirrhosis","diagnosticRequired":null,"brandNameForIndication":"Diuril"},{"id":"chlorothiazide-edema-in-corticosteroid-therap","name":"Edema in Corticosteroid Therapy","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with edema due to corticosteroid therapy","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with edema due to corticosteroid therapy","diagnosticRequired":null,"brandNameForIndication":"Diuril"},{"id":"chlorothiazide-edema-in-estrogen-therapy","name":"Edema in Estrogen Therapy","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with edema due to estrogen therapy","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with edema due to estrogen therapy","diagnosticRequired":null,"brandNameForIndication":"Diuril"},{"id":"chlorothiazide-edema-in-nephrotic-syndrome","name":"Edema in Nephrotic Syndrome","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with edema due to nephrotic syndrome","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with edema due to nephrotic syndrome","diagnosticRequired":null,"brandNameForIndication":"Diuril"},{"id":"chlorothiazide-edema-in-acute-glomerulonephri","name":"Edema in Acute Glomerulonephritis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with edema due to acute glomerulonephritis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with edema due to acute glomerulonephritis","diagnosticRequired":null,"brandNameForIndication":"Diuril"},{"id":"chlorothiazide-edema-in-chronic-renal-failure","name":"Edema in Chronic Renal Failure","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with edema due to chronic renal failure","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with edema due to chronic renal failure","diagnosticRequired":null,"brandNameForIndication":"Diuril"},{"id":"chlorothiazide-pathologic-edema-in-pregnancy","name":"Pathologic Edema in Pregnancy","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Pregnant patients with edema due to pathologic causes","pivotalTrial":null,"restrictions":[],"patientPopulation":"Pregnant patients with edema due to pathologic causes","diagnosticRequired":null,"brandNameForIndication":"Diuril"},{"id":"chlorothiazide-severe-discomforting-edema-in-","name":"Severe Discomforting Edema in Pregnancy","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Pregnant patients with severe discomforting edema not relieved by rest","pivotalTrial":null,"restrictions":[],"patientPopulation":"Pregnant patients with severe discomforting edema not relieved by rest","diagnosticRequired":null,"brandNameForIndication":"Diuril"}],"offLabel":[{"name":"Calcium renal calculus","source":"DrugCentral","drugName":"CHLOROTHIAZIDE","evidenceCount":113,"evidenceLevel":"strong"},{"name":"Nephrogenic diabetes insipidus","source":"DrugCentral","drugName":"CHLOROTHIAZIDE","evidenceCount":84,"evidenceLevel":"strong"}],"pipeline":[]},"currentOwner":"Salix Pharms","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"bendroflumethiazide","brandName":"bendroflumethiazide","genericName":"bendroflumethiazide","approvalYear":"1959","relationship":"same-class"},{"drugId":"hydroflumethiazide","brandName":"hydroflumethiazide","genericName":"hydroflumethiazide","approvalYear":"1959","relationship":"same-class"},{"drugId":"hydrochlorothiazide","brandName":"hydrochlorothiazide","genericName":"hydrochlorothiazide","approvalYear":"1959","relationship":"same-class"},{"drugId":"polythiazide","brandName":"polythiazide","genericName":"polythiazide","approvalYear":"1961","relationship":"same-class"},{"drugId":"trichlormethiazide","brandName":"trichlormethiazide","genericName":"trichlormethiazide","approvalYear":"1960","relationship":"same-class"},{"drugId":"methylclothiazide","brandName":"methylclothiazide","genericName":"methylclothiazide","approvalYear":"1960","relationship":"same-class"},{"drugId":"cyclothiazide","brandName":"cyclothiazide","genericName":"cyclothiazide","approvalYear":"1982","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07469722","phase":"PHASE2,PHASE3","title":"POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2026-03-23","conditions":["Acute Heart Failure (AHF)","Congestive Heart Failure Acute","Diuretic Effect","Lung Ultrasonography Score","Ultrasonography, Doppler","Point-of-care Ultrasound (POCUS)"],"enrollment":128,"completionDate":"2028-07-01"},{"nctId":"NCT07458880","phase":"NA","title":"Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-01","conditions":["Intracerebral Hemorrhage"],"enrollment":140,"completionDate":"2030-06-30"},{"nctId":"NCT05373264","phase":"PHASE3","title":"HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2024-07-31","conditions":["ADPKD"],"enrollment":300,"completionDate":"2031-07"},{"nctId":"NCT06041529","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2023-10-18","conditions":["Essential Hypertension"],"enrollment":198,"completionDate":"2026-02-28"},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":["Lactating Women on Select DOI","Breastfed Infants of Mothers on Select DOI"],"enrollment":1600,"completionDate":"2027-07-31"},{"nctId":"NCT03892148","phase":"PHASE4","title":"Protocol of Diuretics Use in Congestive Therapy in Heart Failure","status":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2019-05-17","conditions":["Heart Failure","Acute Heart Failure","Chronic Heart Failure"],"enrollment":299,"completionDate":"2023-01-16"},{"nctId":"NCT03481881","phase":"","title":"Pharmacokinetics of Drugs Administered to Children","status":"RECRUITING","sponsor":"Duke University","startDate":"2013-08-14","conditions":["Pediatric ALL"],"enrollment":200,"completionDate":"2033-08-14"},{"nctId":"NCT05171686","phase":"PHASE4","title":"Diuretics and Volume Overload in Early CKD","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2023-02-01","conditions":["Chronic Kidney Disease","Hypertension"],"enrollment":49,"completionDate":"2025-10-02"},{"nctId":"NCT07271420","phase":"PHASE4","title":"Blood Pressure Control With Thiazide Diuretics in Peritoneal Dialysis Patients","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2020-01-01","conditions":["Hypertension","Peritoneal Dialysis","End Stage Kidney Disease (ESRD)"],"enrollment":40,"completionDate":"2027-06-30"},{"nctId":"NCT02483936","phase":"PHASE3","title":"Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"","conditions":["Arterial Hypertension"],"enrollment":0,"completionDate":""},{"nctId":"NCT05125224","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-10-01","conditions":["Hypertension"],"enrollment":163720,"completionDate":"2023-12-31"},{"nctId":"NCT04676399","phase":"EARLY_PHASE1","title":"Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-02-08","conditions":["Chronic Pain","Hypertension","Diuretics Drug Reactions","SCS"],"enrollment":36,"completionDate":"2027-12"},{"nctId":"NCT02546583","phase":"PHASE1","title":"Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure","status":"COMPLETED","sponsor":"Yale University","startDate":"2015-08-31","conditions":["Heart Failure"],"enrollment":458,"completionDate":"2020-01-23"},{"nctId":"NCT04654312","phase":"PHASE1","title":"Study to Evaluate the Influence of Hydrochlorothiazide on Dermal Photosensitivity and DNA Stability - a Pilot Study (HCTox Study)","status":"COMPLETED","sponsor":"Universität des Saarlandes","startDate":"2021-01-18","conditions":["Photosensitivity"],"enrollment":30,"completionDate":"2021-07-22"},{"nctId":"NCT04423627","phase":"EARLY_PHASE1","title":"Sympathetic Regulation of Large Artery Stiffness in Humans With ISH","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2021-06-01","conditions":["Hypertension, Systolic","Stiffness, Aortic"],"enrollment":100,"completionDate":"2025-07-31"},{"nctId":"NCT02373163","phase":"PHASE4","title":"INTERVENCION Trial","status":"COMPLETED","sponsor":"Prevencion","startDate":"2014-09-01","conditions":["Blood Pressure, High"],"enrollment":166,"completionDate":"2016-06-01"},{"nctId":"NCT03295734","phase":"PHASE2","title":"ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-05-29","conditions":["Hypertension","Aging","Sedentary Lifestyle"],"enrollment":223,"completionDate":"2024-09-19"},{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":["Hypertension"],"enrollment":702,"completionDate":"2025-05-01"},{"nctId":"NCT07020104","phase":"NA","title":"The Role of Skin Sodium Accumulation in Chronic Kidney Disease","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2025-01-07","conditions":["Chronic Kidney Diseases"],"enrollment":60,"completionDate":"2039-12-01"},{"nctId":"NCT03476551","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Hydrochlorothiazide","status":"RECRUITING","sponsor":"Norwegian University of Science and Technology","startDate":"2016-11-02","conditions":["Obesity, Morbid"],"enrollment":12,"completionDate":"2026-10"},{"nctId":"NCT04934228","phase":"PHASE1","title":"Mitigating the Pro-inflammatory Phenotype of Obesity","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2021-07-01","conditions":["Blood Pressure","Diabetes","Obesity","Insulin Resistance","Diuretics Drug Reactions","Sympathetic Nerve Activity"],"enrollment":60,"completionDate":"2027-08-01"},{"nctId":"NCT03946514","phase":"PHASE4","title":"Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-09-01","conditions":["Hypertension"],"enrollment":180,"completionDate":"2024-08-31"},{"nctId":"NCT06205407","phase":"PHASE1","title":"A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-12-26","conditions":["Healthy Participants"],"enrollment":42,"completionDate":"2024-03-01"},{"nctId":"NCT04927299","phase":"PHASE3","title":"Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2022-06-30","conditions":["Essential Arterial Hypertension"],"enrollment":163,"completionDate":"2023-09-11"},{"nctId":"NCT06362668","phase":"NA","title":"EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU)","status":"COMPLETED","sponsor":"Reprieve Cardiovascular, Inc","startDate":"2024-05-17","conditions":["Acute Decompensated Heart Failure"],"enrollment":12,"completionDate":"2024-10-31"},{"nctId":"NCT06111885","phase":"PHASE2","title":"Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2024-10-01","conditions":["Kidney Stone"],"enrollment":99,"completionDate":"2027-06-30"},{"nctId":"NCT06681116","phase":"NA","title":"Use of Nanotechnology Structured Water for the Prevention of Recurrent Stone Formation","status":"COMPLETED","sponsor":"ALI KAMAL M. SAMI","startDate":"2015-02-16","conditions":["Renal Stones","Idiopathic Hypercalciuria"],"enrollment":325,"completionDate":"2020-08-24"},{"nctId":"NCT00690521","phase":"NA","title":"A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2004-10-26","conditions":["Congestive Heart Failure"],"enrollment":8,"completionDate":"2009-11-10"},{"nctId":"NCT04334824","phase":"","title":"Hydrochlorothiazide and Risk of Skin Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2019-05-27","conditions":["Non-melanoma Skin Cancer","Melanoma","Hypertension"],"enrollment":2953748,"completionDate":"2021-03-05"},{"nctId":"NCT00307060","phase":"PHASE3","title":"MK0954A-264 Filter Study (0954A-264)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12-01","conditions":["Mild to Severe Hypertension"],"enrollment":274,"completionDate":"2005-06-02"},{"nctId":"NCT00480805","phase":"PHASE3","title":"HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-08-08","conditions":["Type 2 Diabetes Mellitus","Hypertension"],"enrollment":312,"completionDate":"2002-10-16"},{"nctId":"NCT00400218","phase":"PHASE3","title":"Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09-01","conditions":["Hypertension"],"enrollment":62,"completionDate":"2006-07-19"},{"nctId":"NCT00157963","phase":"PHASE4","title":"Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02-05","conditions":["Essential Hypertension"],"enrollment":174,"completionDate":"2006-02-08"},{"nctId":"NCT00140959","phase":"PHASE4","title":"Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02-01","conditions":["Hypertension"],"enrollment":120,"completionDate":"2004-06-30"},{"nctId":"NCT03109795","phase":"PHASE4","title":"Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System","status":"TERMINATED","sponsor":"University of Iowa","startDate":"2017-04-10","conditions":["Anxiety","Hypertension"],"enrollment":35,"completionDate":"2023-06-30"},{"nctId":"NCT05917275","phase":"PHASE4","title":"Multi-Omics to Predict the Blood Pressure Response to Antihypertensives","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2024-04-04","conditions":["Primary Hypertension"],"enrollment":96,"completionDate":"2025-10"},{"nctId":"NCT00496834","phase":"PHASE4","title":"LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-02-01","conditions":["Hypertension"],"enrollment":201,"completionDate":"2009-09-01"},{"nctId":"NCT02185417","phase":"PHASE3","title":"Diuretic Comparison Project","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2016-06-15","conditions":["Hypertension"],"enrollment":20723,"completionDate":"2022-12-29"},{"nctId":"NCT01431508","phase":"PHASE4","title":"A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-08-01","conditions":["Hypertension"],"enrollment":15,"completionDate":"2009-06-01"},{"nctId":"NCT00546754","phase":"PHASE3","title":"BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05-01","conditions":["Hypertension"],"enrollment":808,"completionDate":"2009-05-01"},{"nctId":"NCT00739674","phase":"PHASE3","title":"SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-02-01","conditions":["Hypertension"],"enrollment":992,"completionDate":"2010-01-01"},{"nctId":"NCT00649688","phase":"PHASE1","title":"Fasting Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg and Lopressor HCT® Tablets 100/50 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-01","conditions":["Healthy"],"enrollment":32,"completionDate":"2003-02"},{"nctId":"NCT00649441","phase":"PHASE1","title":"Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-08","conditions":["Healthy"],"enrollment":60,"completionDate":"2003-09"},{"nctId":"NCT00649597","phase":"PHASE1","title":"Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-11","conditions":["Healthy"],"enrollment":56,"completionDate":"2002-12"},{"nctId":"NCT00649233","phase":"PHASE1","title":"Food Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg to Lopressor HCT® Tablets 100/50 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-01","conditions":["Healthy"],"enrollment":32,"completionDate":"2003-02"},{"nctId":"NCT00649038","phase":"PHASE1","title":"Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-12","conditions":["Healthy"],"enrollment":24,"completionDate":"2002-12"},{"nctId":"NCT00649324","phase":"EARLY_PHASE1","title":"Fasting Study of Hydrochlorothiazide Tablets 50 mg to Hydrochlorothiazide Tablets 50 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-10","conditions":["Healthy"],"enrollment":40,"completionDate":"2005-10"},{"nctId":"NCT00648011","phase":"PHASE1","title":"Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-08","conditions":["Healthy"],"enrollment":44,"completionDate":"2003-09"},{"nctId":"NCT01019590","phase":"PHASE1","title":"Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2006-11","conditions":["Healthy"],"enrollment":36,"completionDate":"2006-11"},{"nctId":"NCT01020214","phase":"PHASE1","title":"Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2006-11","conditions":["Healthy"],"enrollment":36,"completionDate":"2006-11"},{"nctId":"NCT03179163","phase":"PHASE1,PHASE2","title":"Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans","status":"TERMINATED","sponsor":"Penn State University","startDate":"2016-07-20","conditions":["Hypertension,Essential"],"enrollment":10,"completionDate":"2022-12-31"},{"nctId":"NCT03057431","phase":"PHASE3","title":"Hydrochlorothiazide for Kidney Stone Recurrence Prevention","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2017-03-09","conditions":["Nephrolithiasis"],"enrollment":416,"completionDate":"2022-04-30"},{"nctId":"NCT05685277","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Pharmtechnology LLC","startDate":"2022-12-28","conditions":["Bioequivalence"],"enrollment":50,"completionDate":"2023-07-31"},{"nctId":"NCT02262780","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-12-01","conditions":["Healthy"],"enrollment":20,"completionDate":""},{"nctId":"NCT03298802","phase":"PHASE3","title":"Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide","status":"UNKNOWN","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2017-11-21","conditions":["Pre-Eclampsia","Gestational Hypertension","Superimposed Pre-Eclampsia","Hypertension, Pregnancy-Induced","Postpartum Pregnancy-Induced Hypertension","Postpartum Preeclampsia"],"enrollment":612,"completionDate":"2024-08-30"},{"nctId":"NCT00170950","phase":"PHASE3","title":"Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension","status":"TERMINATED","sponsor":"Novartis","startDate":"2003-10","conditions":["Hypertension"],"enrollment":11506,"completionDate":"2008-05"},{"nctId":"NCT05443932","phase":"PHASE4","title":"Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2024-03-04","conditions":["Urolithiasis","Hyperoxaluria"],"enrollment":32,"completionDate":"2025-12-31"},{"nctId":"NCT00171015","phase":"PHASE3","title":"VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-12","conditions":["Hypertension"],"enrollment":212,"completionDate":"2005-04"},{"nctId":"NCT02046395","phase":"PHASE4","title":"Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tulane University School of Medicine","startDate":"2012-01","conditions":["Type 2 Diabetes","Hypertension"],"enrollment":28,"completionDate":"2019-12"},{"nctId":"NCT00751829","phase":"PHASE3","title":"Isolated Systolic Hypertension in the Elderly and Very Elderly","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2003-07","conditions":["Isolated Systolic Hypertension"],"enrollment":417,"completionDate":"2005-02"},{"nctId":"NCT05840536","phase":"PHASE4","title":"Combination Diuretic Therapy for Acute Decompensated Heart Failure","status":"WITHDRAWN","sponsor":"Ochsner Health System","startDate":"2014-05","conditions":["Acute Decompensated Heart Failure"],"enrollment":0,"completionDate":"2015-10"},{"nctId":"NCT02711670","phase":"NA","title":"Night Time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium","status":"COMPLETED","sponsor":"VA New York Harbor Healthcare System","startDate":"2014-02","conditions":["Kidney Stones"],"enrollment":10,"completionDate":"2017-06"},{"nctId":"NCT01983462","phase":"PHASE2","title":"Vascular Dysfunction in Human Obesity Hypertension","status":"TERMINATED","sponsor":"Gary L. Pierce","startDate":"2013-10","conditions":["Obesity","Prehypertension","Hypertension"],"enrollment":33,"completionDate":"2020-06"},{"nctId":"NCT03261375","phase":"NA","title":"To Evaluate Safety and Efficacy of a Radiofrequency Renal Denervation System in Treatment of Essential Hypertension","status":"COMPLETED","sponsor":"Shanghai Golden Leaf MedTec Co. Ltd","startDate":"2021-01-19","conditions":["Hypertension"],"enrollment":205,"completionDate":"2022-12-26"},{"nctId":"NCT01692717","phase":"PHASE1","title":"Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Losartana + Hydrochlorothiazide","status":"COMPLETED","sponsor":"Azidus Brasil","startDate":"2013-02-28","conditions":["Healthy Subjects"],"enrollment":90,"completionDate":"2013-05-31"},{"nctId":"NCT01647932","phase":"PHASE3","title":"Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics in Patients With Decompensated Heart Failure","status":"COMPLETED","sponsor":"Spanish Society of Internal Medicine","startDate":"2014-10","conditions":["Heart Failure"],"enrollment":232,"completionDate":"2019-12-15"},{"nctId":"NCT05545059","phase":"PHASE3","title":"Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-09-24","conditions":["Resistant Hypertension"],"enrollment":138,"completionDate":"2023-03-31"},{"nctId":"NCT03461003","phase":"PHASE4","title":"N-of-1 Trials In Children With Hypertension","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-04-02","conditions":["Pediatric Hypertension"],"enrollment":49,"completionDate":"2021-05-02"},{"nctId":"NCT01620788","phase":"PHASE3","title":"Comparison of Losartan Associated With Indapamide Versus Hyzaar® in the Hypertension Treatment","status":"SUSPENDED","sponsor":"EMS","startDate":"2019-11-27","conditions":["Hypertension"],"enrollment":636,"completionDate":"2023-10"},{"nctId":"NCT03205137","phase":"","title":"Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2022-06-01","conditions":["Hypertension"],"enrollment":0,"completionDate":"2022-07-11"},{"nctId":"NCT03387657","phase":"PHASE1","title":"A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-03","conditions":["Type 2 Diabetes Mellitus"],"enrollment":16,"completionDate":"2018-03-02"},{"nctId":"NCT00896389","phase":"PHASE4","title":"Salt Loading and Thiazide Intervention Study","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2009-10","conditions":["Hypertension"],"enrollment":124,"completionDate":"2013-03"},{"nctId":"NCT00092209","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-04","conditions":["Hypertension"],"enrollment":840,"completionDate":"2002-11"},{"nctId":"NCT00953680","phase":"PHASE1","title":"Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-04","conditions":["Hypertension"],"enrollment":77,"completionDate":"2004-07"},{"nctId":"NCT03423355","phase":"PHASE4","title":"Dapagliflozin Effect on Erythropoiesis and Physical Fitness","status":"WITHDRAWN","sponsor":"University Hospital Tuebingen","startDate":"2021-09","conditions":["Type 2 Diabetes Mellitus (T2DM)"],"enrollment":0,"completionDate":"2023-12"},{"nctId":"NCT03971929","phase":"PHASE1","title":"Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-07-31","conditions":["Hypertension"],"enrollment":36,"completionDate":"2020-09-03"},{"nctId":"NCT02742467","phase":"PHASE4","title":"Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans","status":"COMPLETED","sponsor":"University of Abuja","startDate":"2017-06-07","conditions":["Hypertension"],"enrollment":702,"completionDate":"2018-06-01"},{"nctId":"NCT04952051","phase":"PHASE3","title":"Enalapril Folic Acid Tablets Combined With CCB or Diuretic to Prevent Stroke in Patients With Type H Hypertension","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2014-07-01","conditions":["Hypertension"],"enrollment":1000,"completionDate":"2020-07-01"},{"nctId":"NCT02824718","phase":"PHASE2","title":"Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-06","conditions":["Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment"],"enrollment":16,"completionDate":"2020-05-28"},{"nctId":"NCT00667719","phase":"PHASE3","title":"A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-06-05","conditions":["Essential Hypertension"],"enrollment":564,"completionDate":"2009-10-05"},{"nctId":"NCT02278471","phase":"PHASE2","title":"The SCCS Polypill Pilot Trial","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2015-12","conditions":["Hypertension","Hyperlipidemia"],"enrollment":303,"completionDate":"2018-06-27"},{"nctId":"NCT03031496","phase":"PHASE1","title":"Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-03-17","conditions":["Hypertension"],"enrollment":42,"completionDate":"2017-04-10"},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":["Hypertension","COVID"],"enrollment":22213,"completionDate":"2020-12-31"},{"nctId":"NCT03574857","phase":"PHASE4","title":"Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance","status":"TERMINATED","sponsor":"University of Virginia","startDate":"2018-06-01","conditions":["Heart Failure","Heart Failure With Reduced Ejection Fraction","Heart Failure Acute","Cardiovascular Diseases"],"enrollment":5,"completionDate":"2021-01-01"},{"nctId":"NCT02699125","phase":"PHASE4","title":"Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2015-01","conditions":["Obstructive Sleep Apnea"],"enrollment":41,"completionDate":"2016-08"},{"nctId":"NCT02710071","phase":"PHASE4","title":"Treatment of OSA Associated Hypertension With Nebivolol or Hydrochlorothiazide","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2015-01","conditions":["Hypertension"],"enrollment":41,"completionDate":"2016-04"},{"nctId":"NCT02765009","phase":"NA","title":"Effects of Fluid Balance Control in Critically Ill Patients","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2016-06-01","conditions":["Fluid Shifts","Critical Care"],"enrollment":1411,"completionDate":"2020-05-25"},{"nctId":"NCT03170336","phase":"PHASE4","title":"A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2018-03-01","conditions":["Chronic Kidney Diseases"],"enrollment":40,"completionDate":"2020-08-01"},{"nctId":"NCT03978884","phase":"PHASE4","title":"Phase 4 Study of the Efficacy of Losartan Based Therapy in Hypertensives With and Without Diabetes","status":"WITHDRAWN","sponsor":"The University of The West Indies","startDate":"2019-06-01","conditions":["Diabetes Mellitus","Hypertension"],"enrollment":0,"completionDate":"2020-12-31"},{"nctId":"NCT04465123","phase":"PHASE3","title":"Early Sequential Nephron Blockade in Acute Heart Failure Patients: A Randomised, Controlled Study","status":"UNKNOWN","sponsor":"Chiang Mai University","startDate":"2020-08-13","conditions":["Acute Heart Failure","Acute Kidney Injury"],"enrollment":100,"completionDate":"2022-12-31"},{"nctId":"NCT00765947","phase":"PHASE4","title":"Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-09","conditions":["Essential Hypertension ( Mild to Moderate)"],"enrollment":256,"completionDate":"2009-08"},{"nctId":"NCT00523744","phase":"PHASE3","title":"Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-07","conditions":["Hypertension"],"enrollment":257,"completionDate":"2007-12"},{"nctId":"NCT00535925","phase":"PHASE4","title":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":["Diabetic Nephropathy"],"enrollment":850,"completionDate":"2019-05"},{"nctId":"NCT03254849","phase":"PHASE4","title":"Empagliflozin and Sympathetic Nerve Traffic","status":"COMPLETED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2017-12-08","conditions":["Type 2 Diabetes Mellitus"],"enrollment":75,"completionDate":"2020-04-20"},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":["Hypertension","COVID-19"],"enrollment":2414,"completionDate":"2021-12-01"},{"nctId":"NCT04371874","phase":"NA","title":"The Standardized Management of Hypertension in Rural Shaanxi","status":"COMPLETED","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2014-01","conditions":["Hypertension"],"enrollment":1210,"completionDate":"2019-02"},{"nctId":"NCT03246555","phase":"PHASE3","title":"Fimasartan in the Senior Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-07-15","conditions":["The Elderly (≥ 70 Years) With Essential Hypertension"],"enrollment":241,"completionDate":"2019-12-09"},{"nctId":"NCT01519635","phase":"PHASE4","title":"Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2011-10","conditions":["Hypertension"],"enrollment":24,"completionDate":"2014-10"},{"nctId":"NCT00673790","phase":"PHASE4","title":"The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-05-15","conditions":["Hypertension"],"enrollment":537,"completionDate":"2010-07-09"},{"nctId":"NCT04242758","phase":"PHASE4","title":"Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy","status":"UNKNOWN","sponsor":"University of Pisa","startDate":"2019-06-04","conditions":["Renal Function Disorder","Glucose Metabolism Disorders"],"enrollment":30,"completionDate":"2020-04-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection, Suspension","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"Sodium Diuril"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Chlorothiazide Sodium"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"CHLOROTHIAZIDE SODIUM"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Chlorothiazide"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Chlorothiazide Sodium"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"chlorothiazide sodium"},{"form":"SUSPENSION","route":"ORAL","productName":"DIURIL"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146099","MMSL":"169210","NDDF":"002292","UNII":"77W477J15H","VUID":"4017731","CHEBI":"CHEBI:3640","VANDF":"4017731","INN_ID":"636","RXNORM":"2396","UMLSCUI":"C0008273","chemblId":"CHEMBL842","ChEMBL_ID":"CHEMBL842","KEGG_DRUG":"D00519","DRUGBANK_ID":"DB00880","PUBCHEM_CID":"2720","SNOMEDCT_US":"372782002","IUPHAR_LIGAND_ID":"4835","SECONDARY_CAS_RN":"7085-44-1","MESH_DESCRIPTOR_UI":"D002740"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1958-","companyName":"Oak Pharms Akorn","relationship":"Original Developer"},{"period":"present","companyName":"Salix Pharms","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"13%"},"publicationCount":2006,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"C03AA04","allCodes":["C03AA04","C03AB04","C03AH01"]},"biosimilarFilings":[],"originalDeveloper":"Oak Pharms Akorn","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":6,"_genericFilersChecked":true,"genericManufacturerList":["Abc Holding","Hikma Intl Pharms","Lederle","Pharmobedient","Sandoz","Watson Labs"],"status":"approved","companyName":"Salix Pharms","companyId":"salix-pharms","modality":"Small molecule","firstApprovalDate":"1958","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1958-09-04T00:00:00.000Z","mah":"OAK PHARMS AKORN","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1958-09-04T00:00:00.000Z","mah":"OAK PHARMS AKORN","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1958-09-04T00:00:00.000Z","mah":"OAK PHARMS AKORN","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1958-09-04T00:00:00.000Z","mah":"OAK PHARMS AKORN","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1958-09-04T00:00:00.000Z","mah":"OAK PHARMS AKORN","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1958-09-04T00:00:00.000Z","mah":"OAK PHARMS AKORN","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1995-05-23T00:00:00.000Z","mah":"SALIX PHARMS","brand_name_local":null,"application_number":"NDA011870"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2011-07-26T00:00:00.000Z","mah":"SUN PHARM","brand_name_local":null,"application_number":"ANDA091546"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2013-04-22T00:00:00.000Z","mah":"AM REGENT","brand_name_local":null,"application_number":"ANDA202561"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-05-29T00:00:00.000Z","mah":"SAGENT PHARMS INC","brand_name_local":null,"application_number":"ANDA202462"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-10-03T00:00:00.000Z","mah":"GLAND","brand_name_local":null,"application_number":"ANDA218630"},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:11:19.465137+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}